GNBT.OB

[REALDEALS21]

Broke thru the $2 wall !!!!

[Ramsburg]

Back in GNBT here at 1.90, expecting the 200sma to act as closing support (1.8985).

Applaud

[Ramsburg]

Trading Idea:
After we sold our position, GNBT had a correctional move to the breakout zone, we missed an entry on the spot, but after the last two candles we can clearly see some strength again.
$1.85/$1.90 should be a support now, and even with a possible short term consolidation, we expect GNBT to continue its run, so we're jumping back into this position once again.

Trading Plan:
Buy GNBT today at or near the open.
(the stop will be provided on the next update)

[Terliso]

After we sold our position, GNBT had a correctional move to the breakout zone, we missed an entry on the spot, but after the last two candles we can clearly see some strength again.
$1.85/$1.90 should be a support now, and even with a possible short term consolidation, we expect GNBT to continue its run, so we're jumping back into this position once again.

That is a great move Ramsburg... applause

[fous]

im hopping in this one today as well buddy

ive traded gnbt once or twice in the past both for losses trying to catch this thing on the rebound    but i mean come on, 3rd times times a charm right  lol

longer term chart we see $2 as a significant support/resistance area. Price briefly dipped below it to bounce off of the prior breakout zone as well as ascending support to put us back above $2 which looks like a good sign to me.

-fous

[422fwhp]

Isn't that a pretty large float?   

[fous]

Interesting article about a new strain of birdflu in China. Might spark some volatility in the bird flu plays but no movement in GNBT or NVAX AH after this was announced.

By Tan Ee Lyn

HONG KONG (Reuters) - Scientists in Hong Kong and the United States have detected a new strain of H5N1 bird flu virus in China and warned it might have started another wave of outbreaks in poultry in Southeast Asia and move deeper into Eurasia.

The strain, called the "Fujian-like virus" because it was first isolated in China's southern Fujian province in March 2005, has increasingly been detected since October 2005 in poultry in six provinces in China, displacing other H5N1 strains.

The strain might also have become resistant to vaccines, which China began using on a large scale from September 2005 to protect poultry from H5N1, said the scientists.

The researchers are from the University of Hong Kong, including virologists Guan Yi and Malik Peiris, and Rob Webster of St Jude Children's Research Hospital in the United States.

"The predominance of this Fujian-like virus appears to be responsible for the increased prevalence of H5N1 in poultry since October 2005 and recent human infection cases in China," they said in an article published in the U.S.-based Proceedings of the National Academy of Sciences (www.pnas.org).

"It has already caused poultry outbreaks in Laos, Malaysia and Thailand, and human disease in Thailand. It is likely that this variant has already initiated a third wave of transmission throughout Southeast Asia and may spread further in Eurasia."

The first wave of H5N1 outbreaks occurred in late 2003 and 2004 in many parts of Asia. The second wave started in China's Qinghai Lake in May 2005 and that strain has since been found in parts of Europe, Africa and the Middle East.

The virus has killed more than 150 people since late 2003 and remains largely a disease among birds. But experts fear it could trigger a flu pandemic and kill millions of people if it mutates into a strain that can pass from human to human.

[Ramsburg]

Update:
GNBT may be just consolidating the recent run, the ascending support line is now at $1.93.

Trading Plan:
Hold with a stop @ $1.84

Best regards,

[422fwhp]

Looks like it could be breaking out...good reaction off support.

[422fwhp]

Looks like it could be breaking out...good reaction off support.

[mitchjas]

I'm in at 2.06 this morning.  I liked how GNBT bounced off the bottom support yesterday and this morning's volume early on. 

Looking good so far, let's hope it keeps the gain and more tomorrow.

Jason

[nofear]

nice !!!

[nofear]

GNBT is ready to rock and roll

[Se7en]

Drugs and fear: A new bird flu flurry
New strain discovery prompts concern among researchers; may spur languishing biotech treatment investment.
By Aaron Smith, CNNMoney.com staff writer
November 2 2006: 3:06 PM EST

NEW YORK (CNNMoney.com) -- Scientists have discovered a new strain of bird flu that has infected humans in China, which could arouse fresh fears of a possible pandemic and spur further interest in experimental drugs and vaccines.

Dr. Robert Webster of St. Jude's Children's Research Hospital in Memphis, along with other scientists from the U.S. and China, announced "the emergence and pre-dominance of a previously uncharacterized" sub-strain of bird flu, appearing in Chinese poultry since late 2005.
biocryst_pharmaceuticals.03.jpg
Related

    * Sanofi to help make Tamiflu

    * Merck's risky bet on a little biotech

    * The threat to Big Pharma

The scientists, who published their findings on the Proceedings of the National Academy of Sciences website, also reported that the sub-strain of H5N1, also known as bird flu, had "caused recent human infection in China." Researchers noted that some of these cases were residents of urban areas remote from poultry farms.

"The development of highly pathogenic avian H5N1 influenza viruses in poultry in Eurasia accompanied with the increase in human infection in 2006 suggests that the virus has not been effectively contained and that the pandemic threat persists," the researchers concluded.

Bird flu typically emerges in poultry and wild birds, but the often-fatal virus can be spread to humans who are in close contact with the infected birds. The virus emerged in Asia in 2003, and to date it has infected 256 humans and killed 151, with Vietnam and Indonesia accounting for the majority of cases, according to the World Health Organization.

But there have been only limited incidents of human-to-human transmission, with nothing sustainable. Human-to-human transmission is the greatest fear of health workers around the world, because strong cases of human-to-human transmission have the potential to spark a global pandemic, like the strain of influenza that killed tens of millions in 1918. Health and Human Services has estimated that a pandemic outbreak in the U.S. could kill up to 300,000 people.

And with more than 50 known strains of H5N1, the discovery of a new one doesn't necessarily mean the end is nigh, experts point out.

"I don't consider it that worrisome yet," said Ren Benjamin, biotech analyst for Rodman & Renshaw. "Once it mutates or becomes more pathogenic, then it becomes something to worry about. If you make the discovery that there's human-to-human [transmission,] then the red flag will go up."
Boon for biotechs?

Congress has approved $3.3 billion in funding for anti-viral drugs and vaccines to fight avian flu, less than half the $7.1 billion requested by President Bush. As part of this, HHS has allocated at least $300 million to fund development of anti-virals to decrease dependency on vaccines. Also, the agency has awarded $1 billion to drugmakers to develop a better method of making a vaccine.

BioCryst Pharmaceutical (up $0.02 to $11.44, Charts), an Alabama-based biotech, stands to benefit from increased interest in its experimental anti-viral Peramivir, particularly since its stock price has fallen by nearly a third year-to-date.

"The fact that the [BioCryst] stock has been so depressed suggests that avian flu has been mitigated, but that's not the case," said Vinny Jindal, biotech analyst for ThinkEquity. "It appears to be expanding geographically and becoming more pathogenic."

Peramivir is an experimental anti-viral drug, not a vaccine, which means it would be injected as a treatment after the patient is infected. Vaccines are injected prior to infection, with the intention of fighting the virus before it takes effect.

But will Peramivir be effective against the newly discovered strain of H5N1?

"We have actually evaluated Peramivir against 53 H5N1 strains already, and Peramivir is potent against all those strains," said Dr. Shane Arnold, director of Peramivir research for BioCryst. "We believe that Peramivir will be effective [against the new strain,] but until we do the study we can't know for sure."

Roche Holding (Charts), the Swiss drug company that produces the anti-viral Tamiflu, could also benefit from increased interest in H5N1. Tamiflu is the only bird flu treatment currently on the market, though some analysts believe that Peramivir has better potential in fighting the disease.

Sanofi-Aventis (down $0.29 to $42.14, Charts), the French drugmaker, is considered a lead company in developing a bird flu vaccine. But even if a successful vaccine is developed, there is a concern in the health community that it wouldn't be distributed to the population in time to ward off mass infection in the event of a pandemic.
No flu shot shortage ... this year

Other companies working on potential bird flu treatments include Generex Biotechnology (up $0.11 to $2.13, Charts), Novavax (down $0.06 to $4.24, Charts) and Avi Biopharma (Charts).

"Anytime that a new strain or a new variant is discovered or highlighted in the media, that's good news for any company working in the anti-viral space for avian flu, or even the vaccine space, because it shows the potential for a pandemic is real," said Ren Benjamin, of Rodman & Renshaw.


http://money.cnn.com/2006/11/02/news/companies/birdflu/index.htm?source=yahoo_quote

[Ramsburg]

Update:

Headlines:
• Biotechs could benefit from new bird flu strain
• Generex Biotechnology Sponsors Episode of Medical Missions for Children "Plain Talk About Health" Program on Avian Influenza

Bird flu is on the news, and GNBT had some visibility today...
First it was SVA, then NVAX, now GNBT, they all are getting some attentions from time to time, but looking from other side, this is part of a bigger picture. First some technical reversal patterns (a few months ago), then some consolidation (now), and its expectable a new rally on this sector, at least I'm enjoying this stocks behaviour in general, and I'm kind of comfortable holding them as a group.
Let's wait...

Trading Plan:
Hold with a stop @ $1.84

Best regards,